Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Darius Lakdawalla, PhD

    TitleProfessor of Pharmaceutical Economics and Public Policy and Quintiles Chair in Pharmaceutical and Regulatory innovation
    SchoolSchool of Pharmacy
    DepartmentPharmacology and Pharmaceutical Sciences
    Address635 Downey Way, VPD 414-K
    Off Campus
    Los Angeles California 90089
    Phone+1 213 538 8736
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Darius Lakdawalla is a Professor in the University of Southern California (USC) School of Pharmacy and in the Sol Price School of Public Policy, and holds the Quintiles Chair in Pharmaceutical Development and Regulatory Innovation. Dr. Lakdawalla is also Director of Research at the Leonard D. Schaeffer Center for Health Policy and Economics at USC.

      He has been the recipient of the Milken Institute’s Distinguished Economic Research Award for best research in the field of economics, and the recipient of the Garfield Prize for research on the economics of medical innovation. His work has been published in leading journals of economics, medicine, and health policy, and funded by the National Institute of Aging, the National Institute of Child Health and Human Development, and the National Bureau of Economic Research.

      Dr. Lakdawalla is currently a Research Associate in the Health Care and Health Economics programs at the National Bureau of Economic Research, in Cambridge, Mass., and a Visiting Scholar at the American Enterprise Institute. He serves as an Associate Editor at the Review of Economics and Statistics. He is also the former Director of Research at the Bing Center for Health Economics at the RAND Corporation.

      Dr. Lakdawalla received his BS in mathematics and philosophy from Amherst College and his PhD in economics from the University of Chicago.


      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Shafrin J, May SG, Shrestha A, Ruetsch C, Gerlanc N, Forma F, Hatch A, Lakdawalla D, Lindenmayer JP. Access to credible information on schizophrenia patients' medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers. Patient Prefer Adherence. 2017; 11:1071-1081. PMID: 28721020.
        View in: PubMed
      2. Shafrin J, Forma F, Scherer E, Hatch A, Vytlacil E, Lakdawalla D. The cost of adherence mismeasurement in serious mental illness: a claims-based analysis. Am J Manag Care. 2017 May 01; 23(5):e156-e163. PMID: 28810130.
        View in: PubMed
      3. Bognar K, Romley JA, Bae JP, Murray J, Chou JW, Lakdawalla D. The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions. J Health Econ. 2017 Jan; 51:1-12. PMID: 27992772.
        View in: PubMed
      4. Shafrin J, Schwartz TT, Lakdawalla D, Forma FM. Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia. J Manag Care Spec Pharm. 2016 Nov; 22(11):1285-1291. PMID: 27783545.
        View in: PubMed
      5. MacEwan JP, Forma FM, Shafrin J, Hatch A, Lakdawalla D, Lindenmayer JP. Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia. J Manag Care Spec Pharm. 2016 Nov; 22(11):1349-1361. PMID: 27783548.
        View in: PubMed
      6. Shih T, Wakeford C, Meletiche D, Sussell J, Chung A, Liu Y, Shim JJ, Lakdawalla D. Reconsidering the economic value of multiple sclerosis therapies. Am J Manag Care. 2016 Nov 01; 22(11):e368-e374. PMID: 27849348.
        View in: PubMed
      7. Jena AB, Zhang J, Lakdawalla D. The Trade-off Between Speed and Safety in Drug Approvals. JAMA Oncol. 2016 Sep 29. PMID: 27684643.
        View in: PubMed
      8. Lakdawalla D, Linthicum MT, Vanderpuye-Orgle J. Does patient cost sharing for HCV drugs make sense? Am J Manag Care. 2016 May; 22(6 Spec No.):SP188-90. PMID: 27266947.
        View in: PubMed
      9. Jena AB, Stevens W, Gonzalez YS, Marx SE, Juday T, Lakdawalla D, Philipson TJ. The wider public health value of HCV treatment accrued by liver transplant recipients. Am J Manag Care. 2016 May; 22(6 Spec No.):SP212-9. PMID: 27266951.
        View in: PubMed
      10. Linthicum MT, Gonzalez YS, Mulligan K, Moreno GA, Dreyfus D, Juday T, Marx SE, Lakdawalla D, Edlin BR, Brookmeyer R. Value of expanding HCV screening and treatment policies in the United States. Am J Manag Care. 2016 May; 22(6 Spec No.):SP227-35. PMID: 27266953.
        View in: PubMed
      11. Moreno GA, Mulligan K, Huber C, Linthicum MT, Dreyfus D, Juday T, Marx SE, Gonzalez YS, Brookmeyer R, Lakdawalla D. Costs and spillover effects of private insurers' coverage of hepatitis C treatment. Am J Manag Care. 2016 May; 22(6 Spec No.):SP236-44. PMID: 27266954.
        View in: PubMed
      12. Shafrin J, Brookmeyer R, Peneva D, Park J, Zhang J, Figlin RA, Lakdawalla D. The value of surrogate endpoints for predicting real-world survival across five cancer types. Curr Med Res Opin. 2016; 32(4):731-9. PMID: 26743800.
        View in: PubMed
      13. Seabury SA, Lakdawalla D, Dougherty JS, Sullivan J, Goldman DP. Medication adherence and measures of health plan quality. Am J Manag Care. 2015 Jun 01; 21(6):e379-89. PMID: 26247579.
        View in: PubMed
      14. Snider JT, Jena AB, Linthicum MT, Hegazi RA, Partridge JS, LaVallee C, Lakdawalla D, Wischmeyer PE. Effect of hospital use of oral nutritional supplementation on length of stay, hospital cost, and 30-day readmissions among Medicare patients with COPD. Chest. 2015 Jun; 147(6):1477-1484. PMID: 25357165; PMCID: PMC4451705.
      15. Eber MR, Goldman DP, Lakdawalla D, Philipson TJ, Pritchard D, Huesch M, Summers N, Linthicum MT, Sullivan J, Dubois RW. Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments. J Comp Eff Res. 2015 May 07; 1-11. PMID: 25951244.
        View in: PubMed
      16. Lakdawalla D, Yin W. Insurers' Negotiating Leverage and the External Effects of Medicare Part D. Rev Econ Stat. 2015 May 01; 97(2):314-331. PMID: 25937676.
        View in: PubMed
      17. Lakdawalla D, Chou JW, Linthicum MT, MacEwan JP, Zhang J, Goldman DP. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer. JAMA Oncol. 2015 May; 1(2):196-202. PMID: 26181023.
        View in: PubMed
      18. Lakdawalla D, Shafrin J, Lucarelli C, Nicholson S, Khan ZM, Philipson TJ. Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains. Health Aff (Millwood). 2015 Apr; 34(4):555-61. PMID: 25847636; PMCID: PMC4406284.
      19. Romley JA, Axeen S, Lakdawalla D, Chernew ME, Bhattacharya J, Goldman DP. The Relationship between Commercial Health Care Prices and Medicare Spending and Utilization. Health Serv Res. 2015 Jun; 50(3):883-96. PMID: 25429755; PMCID: PMC4450935.
      20. Lakdawalla D, Thornton SJ, Perlroth D, LaVallee C, Linthicum MT, Philipson TJ, Partridge J, Wischmeyer P. Effect of Oral Nutritional Supplements On Hospital Outcomes in Patients Aged 65+ With Congestive Heart Failure. Value Health. 2014 Nov; 17(7):A503. PMID: 27201530.
        View in: PubMed
      21. Linthicum MT, Thornton Snider J, Vaithianathan R, Wu Y, LaVallee C, Lakdawalla D, Benner JE, Philipson TJ. Economic burden of disease-associated malnutrition in China. Asia Pac J Public Health. 2015 May; 27(4):407-17. PMID: 25301845.
        View in: PubMed
      22. Snider JT, Linthicum MT, Wu Y, LaVallee C, Lakdawalla D, Hegazi R, Matarese L. Economic burden of community-based disease-associated malnutrition in the United States. JPEN J Parenter Enteral Nutr. 2014 Nov; 38(2 Suppl):77S-85S. PMID: 25249028.
        View in: PubMed
      23. Lakdawalla D, Mascarenhas M, Jena AB, Vanderpuye-Orgle J, LaVallee C, Linthicum MT, Snider JT. Impact of oral nutrition supplements on hospital outcomes in pediatric patients. JPEN J Parenter Enteral Nutr. 2014 Nov; 38(2 Suppl):42S-9S. PMID: 25233942.
        View in: PubMed
      24. Gupta C, Chertow GM, Linthicum MT, Van Nuys K, Belozeroff V, Quarles D, Lakdawalla D. Reforming medicare's dialysis payment policies: implications for patients with secondary hyperparathyroidism. Health Serv Res. 2014 Dec; 49(6):1925-43. PMID: 25040130; PMCID: PMC4254132.
      25. Goldman D, Fastenau J, Dirani R, Helland E, Joyce G, Conrad R, Lakdawalla D. Medicaid prior authorization policies and imprisonment among patients with schizophrenia. Am J Manag Care. 2014 Jul; 20(7):577-86. PMID: 25295404.
        View in: PubMed
      26. Kaestner R, Darden M, Lakdawalla D. Are investments in disease prevention complements? The case of statins and health behaviors. J Health Econ. 2014 Jul; 36:151-63. PMID: 24814322; PMCID: PMC4063305.
      27. Mangalmurti S, Seabury SA, Chandra A, Lakdawalla D, Oetgen WJ, Jena AB. Medical professional liability risk among US cardiologists. Am Heart J. 2014 May; 167(5):690-6. PMID: 24766979; PMCID: PMC4153384.
      28. Seabury SA, Goldman DP, Kalsekar I, Sheehan JJ, Laubmeier K, Lakdawalla D. Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid. Am J Manag Care. 2014 Feb 01; 20(2):e52-60. PMID: 24738555.
        View in: PubMed
      29. Lakdawalla D, Jena AB, Doctor JN. Careful use of science to advance the debate on the UK Cancer Drugs Fund. JAMA. 2014 Jan 01; 311(1):25-6. PMID: 24381964; PMCID: PMC3887550.
      30. Lakdawalla D, Sood N, Gu Q. Pharmaceutical advertising and Medicare Part D. J Health Econ. 2013 Dec; 32(6):1356-67. PMID: 24308884; PMCID: PMC3855652.
      31. Solomon MD, Vijan S, Forma FM, Conrad RM, Summers NT, Lakdawalla D. The impact of insulin type on severe hypoglycaemia events requiring inpatient and emergency department care in patients with type 2 diabetes. Diabetes Res Clin Pract. 2013 Dec; 102(3):175-82. PMID: 24188928.
        View in: PubMed
      32. Turakhia MP, Solomon MD, Jhaveri M, Davis P, Eber MR, Conrad R, Summers N, Lakdawalla D. Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation. Am Heart J. 2013 Sep; 166(3):573-80. PMID: 24016509.
        View in: PubMed
      33. Lakdawalla D, Sood N. Health Insurance as a Two-Part Pricing Contract. J Public Econ. 2013 Jun 01; 102:1-12. PMID: 23997354.
        View in: PubMed
      34. Lakdawalla D, Turakhia MP, Jhaveri M, Mozaffari E, Davis P, Bradley L, Solomon MD. Comparative effectiveness of antiarrhythmic drugs on cardiovascular hospitalization and mortality in atrial fibrillation. J Comp Eff Res. 2013 May; 2(3):301-12. PMID: 24236629.
        View in: PubMed
      35. Lakdawalla D, Eber MR, Forma FM, Sullivan J, Michaud PC, Bradley LA, Goldman DP. Measuring the value of better diabetes management. Am J Manag Care. 2013 Mar-Apr; 19 Spec No. 2:E11. PMID: 23725237.
        View in: PubMed
      36. Chernew ME, McKellar R, Aubry W, Beck R, Benner J, Berger JE, Fendrick AM, Forma F, Goldman D, Peters Harmel A, Killion R, Lakdawalla D, Owens DK, Stahl J. Comparative effectiveness research and formulary placement: the case of diabetes. Am J Manag Care. 2013 Feb; 19(2):93-6. PMID: 23448106.
        View in: PubMed
      37. Philipson TJ, Snider JT, Lakdawalla D, Stryckman B, Goldman DP. Impact of oral nutritional supplementation on hospital outcomes. Am J Manag Care. 2013 Feb; 19(2):121-8. PMID: 23448109.
        View in: PubMed
      38. Seabury SA, Chandra A, Lakdawalla D, Jena AB. On average, physicians spend nearly 11 percent of their 40-year careers with an open, unresolved malpractice claim. Health Aff (Millwood). 2013 Jan; 32(1):111-9. PMID: 23297278.
        View in: PubMed
      39. Lakdawalla D, Seabury SA. The Welfare Effects of Medical Malpractice Liability. Int Rev Law Econ. 2012 Dec; 32(4):356-369. PMID: 23526860.
        View in: PubMed
      40. Huesch M, Lakdawalla D. Freedom to innovate: the perils of centralized medical research. Arch Intern Med. 2012 Nov 26; 172(21):1692-3; author reply 1693. PMID: 23183865.
        View in: PubMed
      41. Darkow T, Maclean R, Joyce GF, Goldman D, Lakdawalla D. Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia. Am J Manag Care. 2012 Nov; 18(11 Suppl):S272-8. PMID: 23327459.
        View in: PubMed
      42. Yin W, Penrod JR, Maclean R, Lakdawalla D, Philipson T. Value of survival gains in chronic myeloid leukemia. Am J Manag Care. 2012 Nov; 18(11 Suppl):S257-64. PMID: 23327457.
        View in: PubMed
      43. Grabowski DC, Lakdawalla D, Goldman DP, Eber M, Liu LZ, Abdelgawad T, Kuznik A, Chernew ME, Philipson T. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff (Millwood). 2012 Oct; 31(10):2276-85. PMID: 23048109.
        View in: PubMed
      44. Jena AB, Chandra A, Lakdawalla D, Seabury S. Outcomes of medical malpractice litigation against US physicians. Arch Intern Med. 2012 Jun 11; 172(11):892-4. PMID: 22825616.
        View in: PubMed
      45. Michaud PC, Goldman DP, Lakdawalla D, Zheng Y, Gailey AH. The value of medical and pharmaceutical interventions for reducing obesity. J Health Econ. 2012 Jul; 31(4):630-43. PMID: 22705389; PMCID: PMC3600147.
      46. Seabury S, Chandra A, Lakdawalla D, Jena AB. Defense costs of medical malpractice claims. N Engl J Med. 2012 Apr 05; 366(14):1354-6. PMID: 22475613.
        View in: PubMed
      47. Lakdawalla D, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood). 2012 Apr; 31(4):676-82. PMID: 22492883.
        View in: PubMed
      48. Seabury SA, Goldman DP, Maclean JR, Penrod JR, Lakdawalla D. Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates. Health Aff (Millwood). 2012 Apr; 31(4):691-9. PMID: 22492885.
        View in: PubMed
      49. Philipson T, Eber M, Lakdawalla D, Corral M, Conti R, Goldman DP. An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer. Health Aff (Millwood). 2012 Apr; 31(4):667-75. PMID: 22492882; PMCID: PMC3829769.
      50. Lakdawalla D, Philipson T. Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets. J Law Econ. 2012 Feb 01; 55(1):151-187. PMID: 25221349.
        View in: PubMed
      51. Faulkner GE, Grootendorst P, Nguyen VH, Andreyeva T, Arbour-Nicitopoulos K, Auld MC, Cash SB, Cawley J, Donnelly P, Drewnowski A, Dubé L, Ferrence R, Janssen I, Lafrance J, Lakdawalla D, Mendelsen R, Powell LM, Traill WB, Windmeijer F. Economic instruments for obesity prevention: results of a scoping review and modified Delphi survey. Int J Behav Nutr Phys Act. 2011 Oct 06; 8:109. PMID: 21978599; PMCID: PMC3207922.
      52. Jena AB, Seabury S, Lakdawalla D, Chandra A. Malpractice risk according to physician specialty. N Engl J Med. 2011 Aug 18; 365(7):629-36. PMID: 21848463; PMCID: PMC3204310.
      53. Michaud PC, Goldman D, Lakdawalla D, Gailey A, Zheng Y. Differences in health between Americans and Western Europeans: Effects on longevity and public finance. Soc Sci Med. 2011 Jul; 73(2):254-63. PMID: 21719178; PMCID: PMC3383030.
      54. Goldman DP, Lakdawalla D, Malkin JD, Romley J, Philipson T. The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial data. Health Aff (Millwood). 2011 Jan; 30(1):84-90. PMID: 21209443; PMCID: PMC3804334.
      55. Goldman D, Lakdawalla D, Philipson TJ, Yin W. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA. Health Econ. 2010 Oct; 19(10):1109-16. PMID: 20842680.
        View in: PubMed
      56. Jena AB, Goldman DP, Kamdar A, Lakdawalla D, Lu Y. Sexually transmitted diseases among users of erectile dysfunction drugs: analysis of claims data. Ann Intern Med. 2010 Jul 06; 153(1):1-7. PMID: 20621899; PMCID: PMC3673772.
      57. Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, Fortuny J. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010 Jul; 26(7):1587-97. PMID: 20429823.
        View in: PubMed
      58. Lakdawalla D, Sun EC, Jena AB, Reyes CM, Goldman DP, Philipson TJ. An economic evaluation of the war on cancer. J Health Econ. 2010 May; 29(3):333-46. PMID: 20363520.
        View in: PubMed
      59. Gailey A, Lakdawalla D, Sood N. Patents, innovation, and the welfare effects of Medicare Part D. Adv Health Econ Health Serv Res. 2010; 22:317-44. PMID: 20575239; PMCID: PMC3988702.
      60. Goldman DP, Jena AB, Lakdawalla D, Malin JL, Malkin JD, Sun E. The value of specialty oncology drugs. Health Serv Res. 2010 Feb; 45(1):115-32. PMID: 19878344; PMCID: PMC2813440.
      61. Lakdawalla D, Philipson T. The growth of obesity and technological change. Econ Hum Biol. 2009 Dec; 7(3):283-93. PMID: 19748839; PMCID: PMC2767437.
      62. Lakdawalla D, Sood N. Innovation and The Welfare Effects of Public Drug Insurance. J Public Econ. 2009 Apr 01; 93(3-4):541-548. PMID: 20454467.
        View in: PubMed
      63. Stewart KA, Grabowski DC, Lakdawalla D. Annual expenditures for nursing home care: private and public payer price growth, 1977 to 2004. Med Care. 2009 Mar; 47(3):295-301. PMID: 19194339; PMCID: PMC2763425.
      64. Sood N, de Vries H, Gutierrez I, Lakdawalla D, Goldman DP. The effect of regulation on pharmaceutical revenues: experience in nineteen countries. Health Aff (Millwood). 2009 Jan-Feb; 28(1):w125-37. PMID: 19088100; PMCID: PMC3829766.
      65. Lakdawalla D, Goldman DP, Michaud PC, Sood N, Lempert R, Cong Z, de Vries H, Gutierrez I. U.S. pharmaceutical policy in a global marketplace. Health Aff (Millwood). 2009 Jan-Feb; 28(1):w138-50. PMID: 19088101; PMCID: PMC3804349.
      66. Bhattacharya J, Choudhry K, Lakdawalla D. Chronic disease and severe disability among working-age populations. Med Care. 2008 Jan; 46(1):92-100. PMID: 18162861.
        View in: PubMed
      67. Lakdawalla D, Goldman DP, Shang B. The health and cost consequences of obesity among the future elderly. Health Aff (Millwood). 2005; 24 Suppl 2:W5R30-41. PMID: 16186149.
        View in: PubMed
      68. Goldman DP, Shang B, Bhattacharya J, Garber AM, Hurd M, Joyce GF, Lakdawalla D, Panis C, Shekelle PG. Consequences of health trends and medical innovation for the future elderly. Health Aff (Millwood). 2005; 24 Suppl 2:W5R5-17. PMID: 16186147.
        View in: PubMed
      69. Bhattacharya J, Cutler DM, Goldman DP, Hurd MD, Joyce GF, Lakdawalla D, Panis CW, Shang B. Disability forecasts and future Medicare costs. Front Health Policy Res. 2004; 7:75-94. PMID: 15612336.
        View in: PubMed
      70. Lakdawalla D, Bhattacharya J, Goldman DP. Are the young becoming more disabled? Health Aff (Millwood). 2004 Jan-Feb; 23(1):168-76. PMID: 15002639.
        View in: PubMed
      71. Lakdawalla D, Goldman DP, Bhattacharya J, Hurd MD, Joyce GF, Panis CW. Forecasting the nursing home population. Med Care. 2003 Jan; 41(1):8-20. PMID: 12544538.
        View in: PubMed
      72. Lakdawalla D, Bhattacharya J, Goldman DP. A response to the points by Manton and Williamson. Med Care. 2003 Jan; 41(1):28-31. PMID: 12544541.
        View in: PubMed
      73. Goldman DP, Lakdawalla D. A new method for determining patient payments for outpatient drugs. Am J Manag Care. 2002 Feb; 8(2):125, 128, 130. PMID: 11853200.
        View in: PubMed
      Darius's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department